* Rakhimov Z.Ya., **KudratbekovA., * Narzullayeva A.R.

**Cardiologists Association of the Republic of Tajikistan

*Department of Cardiology with the course of clinical pharmacology TIPGPMP

The article is devoted to the study of the use of Meldrony in 30 patients with chronic coronary heart disease, stable angina of II-III class combined with arterial hypertension of II degree with high and very high risk of cardiovascular complications in conditions, Midlands Gorno-Badakhshan Autonomous region of Tajikistan. Among the examined patients on the background of the drug Meldrony in a daily dose of 1000 mg, showed a significant improvement cardiohaemodynamic indicators. Simultaneously, a decrease of the average frequency of angina attacks a day with 2,77±0,26 to 1,52±0,17. Also noted a decrease of the daily quantity of consumed nitroglycerin from 2,4 to±0,23 to 1,4±0,16 and significant increase of tolerance to physical activity detected test 6-minute walk from 388±33 m up to 512±39 m Significantly increased the degree of shortening the anterior-posterior size of the left ventricle and the speed of the circular of the shortening of the fibres infarction. Examine the safety and efficacy of the use of Meldrony patients with stenocardia voltage conditions, Midlands Pamir confirmed distinct antianginal its properties.


1. Veden'eva V.V., Mikhin V.P., Sharova V.G. [Comparative efficiency of cardiocytoprotectors Qudesan and Mildronate in patients with stable exertional angina] Tezisy dokladov Mezhdunarodnogo kongressa «Kardiologiya na perekrestke nauk» sovmestno s V Mezhdunarodnym simpoziumom po ekhokardiografii i sosudistomu ul’trazvuku, XVII ezhegodnoy nauchno-prakticheskoy konferentsiey «Aktual’nye voprosy kardiologii» [Abstracts of reports of the International Congress «Cardiology at the crossroads of science» in conjunction with the V International Symposium of Echocardiography and Vascular Ultrasound, XVII Annual Scientific-Practical Conference «Cardiology Update»]. Tyumen', 2010.

2. Dzerve V Mildronate efficiency in treatment of ischemic heart disease: research results of MILSS II. Kviten, 2010, No. 7, pp. 236.

3. Kiselev A.R., Shvarts V.A., Posnenkova O.M. Effect of drug therapy with Mildronate on quality of life patients with acute myocardial infarction with ST-segment elevation in the early postinfarction period. Consilium Medicum, 2010, No. 12 (5), pp. 94-98.

4. Kuznetsova A.V., Teplyakov A.T. The assessment of the impact of Mildronate on the efficiency antianginal therapy and functional condition of the myocardium in patients with IHD in combination with arterial hypertension, associated with diabetes mellitus type 2. Farmateka, 2007, no. 3, pp. 81-84.

5. Statsenko M.E., Turkina S.V., Sporova O.E. The using of the preparation Cardionate in combination therapy of chronic heart failure of ischemic etiology in patients with metabolic syndrome. Russian Journal of Cardiology, 2010, no. 4, pp. 35-39.

6. Dzerve V., Matisone D., Pozdnyakov Y., Oganov R. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. Sem Cardiovascular Med, 2010, Vol. 16 (3), pp. 1-8.

7. Hanaki Y., Sugiyama S., Ozawa T. Effect of 3-(2,2,2, — trimelhylhydrazinium) propionate, gamma-butyrobetaine hydroxylase inhibitor, on isoproterenol — induced mitochondrial dysfunction. Research Communications in Chemical Pathology and Pharmacology, 1999, Vol. 64, pp. 157-160.

8. Lopaschuk G.D., Barr R., Thomas P.D., Dyck J.R. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of longchain 3-ketoacyl coenzyme a thiolase. Circulation Research, 2005, Vol. 93, pp. 33-37.

9. Mario Marzilli. Preductal MR. Od desetiletykh klinickych zkusenosti s lecbou u stabilni anginy pectoris k novym perspektivam. Medicina po promoci, 2011, Vol. 12 (1), pp. 95-98.

10. Vilnis Dzerve, MILSS I Study Group. A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial «MILSS I». Medicina , 2011, Vol. 47 (10), pp. 544-551.

Information about the authors:

Rahimov Zikriya Yahyaevich — the chair of department of cardiology with course of clinic pharmacology TIPGPMP, the Honored worker of the RT, chief cardiologist of MH of RT, cn. med. sci., docent; work phone: (992 37) 236 4042, mobile phone: (992) 918616091; e-mail: rahimov4419@mail.ru


Back to Top